Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

BANZEL

RUFINAMIDE

Standard Dose
100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview BANZEL is listed in Drugs@FDA under application 021911 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient RUFINAMIDE Form and strength TABLET;ORAL - 100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor EISAI INC Submission history Latest submission status date: 2019-11-28 00:00:00.

Structured Monograph

Clinical summary

Approval overview BANZEL is listed in Drugs@FDA under application 021911 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient RUFINAMIDE Form and strength TABLET;ORAL - 100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor EISAI INC Submission history Latest submission status date: 2019-11-28 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.